Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 15:28:397-407.
doi: 10.1016/j.omtn.2022.03.012. eCollection 2022 Jun 14.

The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer

Junxia Liu  1 , Qinqiu Zhang  1 , Daolu Yang  1 , Fei Xie  1 , Zhaoxia Wang  1
Affiliations
Review

The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer

Junxia Liu et al. Mol Ther Nucleic Acids. .

Abstract

It is well known that long non-coding RNAs (lncRNAs) play an important role in the regulation of tumor genesis and development. They can modulate gene expression of transcriptional regulation, epigenetic regulation of chromatin modification, and post-transcriptional regulation, thus influencing the biological behavior of tumors, such as cell proliferation, apoptosis, cell cycle, invasion, and migration. Tumor angiogenesis not only provides nutrients and helps excrete metabolites, but it also opens a pathway for tumor metastasis. Anti-angiogenic therapy has become one of the effective treatment methods for tumor. But its drug resistance leads to the limitation of clinical application. Recent studies have shown that lncRNAs are closely related to tumor angiogenesis and anti-angiogenic therapy resistance, which provides a new direction for tumor research. lncRNAs are expected to be new targets for tumor therapy. For the first time to our knowledge, this paper reviews advancement of lncRNAs in tumor angiogenesis and anti-angiogenic therapy resistance and further discusses their potential clinical application.

Keywords: MT: non-coding RNAs; angiogenesis; anti-angiogenic therapy; cancer; cancer stem cells; drug resistance; long non-coding RNAs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
Relationship between tumor angiogenesis and immune microenvironment before and after anti-angiogenic therapy
Figure 2
Figure 2
The partial mechanisms of lncRNAs involved in tumor angiogenesis and resistance to anti-angiogenic therapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R.L., Miller K.D., Fuchs H.E. Cancer statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. - PubMed
    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. - PubMed
    1. Lugano R., Ramachandran M., Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol. Life Sci. 2020;77:1745–1770. - PMC - PubMed
    1. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N. Engl. J. Med. 1991;324:1–8. - PubMed
    1. Fox S.B. Tumour angiogenesis and prognosis. Histopathology. 1997;30:294–301. - PubMed

LinkOut - more resources